Antoine Papiernik, Author at Labiotech.eu

About

Antoine Papiernik is a Managing Partner at the life sciences VC firm Sofinnova Partners. He has been an initial investor and active board member in Actelion, ProQR, NovusPharma, Movetis, Mainstay, Pixium Vision and Stentys, among others.

Articles by Antoine Papiernik

Antoine Papiernik Sofinnova Partners life science

Opinion 14 Mar 2022

The Secrets to 50 Years of Success in Life Sciences Investment

The European life sciences venture capital firm Sofinnova Partners is celebrating its 50th birthday this year. Sofinnova’s Chairman and Managing Partner, Antoine Papiernik, outlines key lessons the company has learned…

March 14, 2022 - 7 minutesmins - By Antoine Papiernik

Antoine Papiernik Sofinnova Partners Biotech Entrepreneurs

Opinion 7 Jul 2021

Three Lessons an Investor Can Learn from Biotech Entrepreneurs

Sofinnova Partners’ Chairman and Managing Partner, Antoine Papiernik, describes his company’s ‘Wall of Fame’ showcasing its entrepreneurs and how their years of experience provide a source of inspiration for venture…

July 7, 2021 - 7 minutesmins - By Antoine Papiernik

Opinion 8 Mar 2021

Advice for my Younger Self: How to Be a VC in Life Sciences

Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, looks back at where he was two decades ago and shares what he would tell his younger self about being a…

March 8, 2021 - 5 minutesmins - By Antoine Papiernik

Opinion 30 Sep 2019

Can European Biotech Companies Afford Not to Work with China?

In the current trade standoff between the US and China, Europe has a golden opportunity to gain a competitive advantage. At every healthcare conference I’ve been to recently in the…

September 30, 2019 - 4 minutesmins - By Antoine Papiernik

Opinion 16 Jul 2019

The Business of Biotech: What to Do When the S*#t Hits the Fan

From CEO-itis to FDA-itis, the path of a biotech company is never dull. Whether the oft-repeated saying, “may you live in interesting times,” is a blessing or a curse depends…

July 16, 2019 - 5 minutesmins - By Antoine Papiernik

Opinion 5 Jun 2019

Is Going Public in Europe the Kiss of Death?

The key for a European biotech is to find the money where it is. And that’s not in Europe for the moment. Going public is obviously a necessary evil for…

June 5, 2019 - 6 minutesmins - By Antoine Papiernik

Resources

Categories

The latest news on

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

Americas

Asia Pacific

Europe

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Company

Join Us

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering